APA

Brunnberg U., Mohr M., Noppeney R., Dürk H. A., Sauerland M. C., Müller-Tidow C., Krug U., Koschmieder S., Kessler T., Mesters R. M., Schulz C., Kosch M., Büchner T., Ehninger G., Dührsen U., Serve H. & Berdel W. E. (20120713). Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Brunnberg U, Mohr M, Noppeney R, Dürk H A, Sauerland M C, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters R M, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H and Berdel W E. 20120713. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Brunnberg U., Mohr M., Noppeney R., Dürk H. A., Sauerland M. C., Müller-Tidow C., Krug U., Koschmieder S., Kessler T., Mesters R. M., Schulz C., Kosch M., Büchner T., Ehninger G., Dührsen U., Serve H. and Berdel W. E. (20120713). Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Brunnberg U, Mohr M, Noppeney R, Dürk H A, Sauerland M C, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters R M, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H and Berdel W E. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. : Annals of oncology : official journal of the European Society for Medical Oncology. 20120713.